https://www.pharmaradar360.com/article/9d0367961f54bf35PharmaRadar360en2026-04-08T02:00:00.000ZPharmac invites feedback before possible medicine brand changeshttps://www.pharmaradar360.com/article/78bb0fe214831903PharmaRadar360en2026-04-08T00:00:00.000ZESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infectionshttps://www.pharmaradar360.com/article/01e2e9bd4854aa5bPharmaRadar360en2026-04-07T21:55:07.000ZWhat's New Related to Drugshttps://www.pharmaradar360.com/article/8fc621adb0382f70PharmaRadar360en2026-04-07T21:37:44.000ZEpinephrine Auto-Injector Devices by Amneal and Impax: CDER Alert - FDA Alerts Patients and Health Care Professionals About Device Malfunctionhttps://www.pharmaradar360.com/article/3c3e82bc6cb61f4aPharmaRadar360en2026-04-07T20:11:55.000ZWhat’s New for Biologicshttps://www.pharmaradar360.com/article/3e8184c0c0b6e329PharmaRadar360en2026-04-07T20:01:00.000ZAmneal to Report First Quarter 2026 Results on May 1, 2026https://www.pharmaradar360.com/article/973ddaa7b599300fPharmaRadar360en2026-04-07T19:36:30.000ZeSubmitter Application Historyhttps://www.pharmaradar360.com/article/86147c2bb377ba64PharmaRadar360en2026-04-07T19:14:45.000ZFDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problemshttps://www.pharmaradar360.com/article/10820c9acec1bd66PharmaRadar360en2026-04-07T18:51:03.000ZFDA warns that vapors from alcohol-based hand sanitizers can have side effectshttps://www.pharmaradar360.com/article/79cbfdc1a48df600PharmaRadar360en2026-04-07T18:49:28.000ZFDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)https://www.pharmaradar360.com/article/4ac6c7b37c044524PharmaRadar360en2026-04-07T18:19:40.000ZClinical Investigator Inspection List E-Khttps://www.pharmaradar360.com/article/8ba570bbfccba186PharmaRadar360en2026-04-07T17:58:43.000ZFDA Approves First Generic Dapagliflozin Tabletshttps://www.pharmaradar360.com/article/e1734ae701dfbbb7PharmaRadar360en2026-04-07T17:48:52.000ZClinical Investigator Status (Biologics)https://www.pharmaradar360.com/article/f8de021a9f3b396fPharmaRadar360en2026-04-07T17:14:13.000ZOptimizing Pregnancy Registries Public Workshop - 05/07/2026https://www.pharmaradar360.com/article/61b13122a190cac7PharmaRadar360en2026-04-07T16:00:00.000ZKennedy sidestepping court order sidelining ACIP?https://www.pharmaradar360.com/article/46d318d12d5b11cdPharmaRadar360en2026-04-07T15:46:23.000ZDecision: Human and veterinary medicines: register of licensed manufacturing siteshttps://www.pharmaradar360.com/article/3d3d773b50e88351PharmaRadar360en2026-04-07T15:45:00.000ZTransgene to Participate in Upcoming Investor Meetingshttps://www.pharmaradar360.com/article/76d196d069f30145PharmaRadar360en2026-04-07T15:36:02.000ZRemarks by FDA Chief Scientist Denise Hinton to the Professional Services Council FedHealth Conference - 03/11/2021https://www.pharmaradar360.com/article/36904b3f97761ee5PharmaRadar360en2026-04-07T15:25:08.000ZDecision: Medicines: new manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/795c36db0193809dPharmaRadar360en2026-04-07T15:25:00.000ZNotice: Medicines: terminated and cancelled manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/faed43e9e1789450PharmaRadar360en2026-04-07T15:24:49.000ZDecision: Human medicines: register of licensed wholesale distribution siteshttps://www.pharmaradar360.com/article/21a6edec1caf7afaPharmaRadar360en2026-04-07T15:11:58.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/e1a37f7084840d78PharmaRadar360en2026-04-07T15:00:00.000ZSector tariff now more than a threat – for some Rx companieshttps://www.pharmaradar360.com/article/69a247d6c040ae71PharmaRadar360en2026-04-07T13:00:00.000ZMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/498d71c381684fc9PharmaRadar360en2026-04-07T13:00:00.000ZAllergan Aesthetics Third State-of-the-Art AMI Center Opens in Austinhttps://www.pharmaradar360.com/article/5c3ff9f103b0677bPharmaRadar360en2026-04-07T12:30:00.000ZAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directorshttps://www.pharmaradar360.com/article/b73fdd388f8735ddPharmaRadar360en2026-04-07T12:05:00.000ZEmergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparednesshttps://www.pharmaradar360.com/article/22c8686631dc1d90PharmaRadar360en2026-04-07T12:00:00.000ZAmneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Monthhttps://www.pharmaradar360.com/article/db856c0240490cc2PharmaRadar360en2026-04-07T12:00:00.000ZNatac’s CEO presents SustaiNext as an example of industrial scale-up at the CBE JU Stakeholder Forum 202607/04/2026Industrial biotechnologyAntonio Delgado participated in the panel “From lab to fab: enabling scale up of bio-based…Partners - Natac Grouphttps://www.pharmaradar360.com/article/cdd7493356f30112PharmaRadar360en2026-04-07T11:11:33.000ZLa AEMPS recuerda las condiciones para obtener la licencia previa de funcionamiento para la fabricación a terceros de productos sanitarios y productos sanitarios para diagnóstico in vitrohttps://www.pharmaradar360.com/article/f1e80d2a4d12ea5dPharmaRadar360en2026-04-07T10:00:00.000ZFrom Clinic to Community - The EveryONE Project in Family Medicinehttps://www.pharmaradar360.com/article/0e7d9a7fafcff463PharmaRadar360en2026-04-07T10:00:00.000ZTailoring Digital Diabetes Care for Culture and Languagehttps://www.pharmaradar360.com/article/06a1c299ee5a17a2PharmaRadar360en2026-04-07T07:00:00.000ZSkye Bioscience Presenting at GLP-1-Based Therapeutics Summithttps://www.pharmaradar360.com/article/29ba8e8ec46822b2PharmaRadar360en2026-04-07T02:50:00.000ZThe hidden math behind satisfying can-crushing videoshttps://www.pharmaradar360.com/article/da80f94e3b694b92PharmaRadar360en2026-04-07T00:00:00.000ZResearch & Developmenthttps://www.pharmaradar360.com/article/f64678b8b4df4e06PharmaRadar360en2026-04-07T00:00:00.000ZUSP Revisions: What They Mean for Injectable Drug Quality and Why Packaging Matters More Than Everhttps://www.pharmaradar360.com/article/3c2291e9509c4c63PharmaRadar360en2026-04-07T00:00:00.000Ztuhura biosciences appoints amanda garofalo mshs as senior vice president of clinical operations 302735470https://www.pharmaradar360.com/article/eaa9007bf360d765PharmaRadar360en2026-04-07T00:00:00.000ZPharming Group to participate in April investor conferencesConference attendanceApril 7 2026Pharming Group N.V. today announced that its management will participate in the following investor conferences in the month of April:Read morehttps://www.pharmaradar360.com/article/11c35d24d5834c31PharmaRadar360en2026-04-07T00:00:00.000ZPharmacists at Orion – The many paths a pharmacy degree can open up in the pharmaceutical industry4/7/2026 We are Orion Pharmahttps://www.pharmaradar360.com/article/30180204a79fe025PharmaRadar360en2026-04-07T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/fafc8d888e90b0aaPharmaRadar360en2026-04-07T00:00:00.000ZIR and Shareholder Contactshttps://www.pharmaradar360.com/article/b2f2e6fbe21a3d03PharmaRadar360en2026-04-07T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/8141f875e4789cc2PharmaRadar360en2026-04-07T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/7c3c887a6f1e163ePharmaRadar360en2026-04-07T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/2570cc332712ccddPharmaRadar360en2026-04-07T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/4ab17373e80361e9PharmaRadar360en2026-04-07T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/79162b6bbd567300PharmaRadar360en2026-04-07T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/20171ad0cd160930PharmaRadar360en2026-04-07T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/c31d74752418754fPharmaRadar360en2026-04-07T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/70bd8573fcd9db24PharmaRadar360en2026-04-07T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/191dcccfdbe434dcPharmaRadar360en2026-04-07T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/017bd5fd197d16e3PharmaRadar360en2026-04-07T00:00:00.000ZISPOR Publishes Recommendations on Valuing Child and Adolescent Health for Economic Evaluationshttps://www.pharmaradar360.com/article/d5d1724a5634faa6PharmaRadar360en2026-04-07T00:00:00.000ZGilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipelinehttps://www.pharmaradar360.com/article/aad7ffbb74c89147PharmaRadar360en2026-04-07T00:00:00.000ZThe Analytical Scientist: Vibe Coding Comes to Omicshttps://www.pharmaradar360.com/article/db2fcbe9469635c7PharmaRadar360en2026-04-07T00:00:00.000ZSpot the phish in less than five minuteshttps://www.pharmaradar360.com/article/bab26f4bff950c9aPharmaRadar360en2026-04-07T00:00:00.000ZCell & Gene Covers the “Challenges with Implementing Annex 1 at the Global Level” Session from the 2026 ISPE Aseptic Conferencehttps://www.pharmaradar360.com/article/5699bcb7e99adc87PharmaRadar360en2026-04-07T00:00:00.000ZNuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLChttps://www.pharmaradar360.com/article/d9cda0008ef93b04PharmaRadar360en2026-04-07T00:00:00.000Zacadia pharmaceuticals announces daybue stix trofinetide is now broadly available in the united states for the treatment of rett syndromehttps://www.pharmaradar360.com/article/9312d49da9772aa5PharmaRadar360en2026-04-07T00:00:00.000ZWorld Health Day 2026: unite for health and stand with sciencehttps://www.pharmaradar360.com/article/5f43b9b414f8a1d3PharmaRadar360en2026-04-07T00:00:00.000ZMessage from Dr Hanan Balkhy WHO Regional Director for the Eastern Mediterranean on the occasion of World Health Dayhttps://www.pharmaradar360.com/article/42c4b81b3da7cfc4PharmaRadar360en2026-04-06T12:30:00.000ZAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)https://www.pharmaradar360.com/article/e484886095722acfPharmaRadar360en2026-04-06T11:22:39.000ZCRC Confessionals: The Support I Never Dreamed I Could Havehttps://www.pharmaradar360.com/article/ef9a28bc59b166e5PharmaRadar360en2026-04-06T10:00:00.000ZCancer, climate change, fossil fuels, and war: a call for actionhttps://www.pharmaradar360.com/article/4293c44a9ae754e4PharmaRadar360en2026-04-06T10:00:00.000ZSound mind, sound place: ibasho and post-disaster mental healthhttps://www.pharmaradar360.com/article/33371b9233a32748PharmaRadar360en2026-04-06T10:00:00.000ZQ&A: Ezekiel Emanuel's simple ruleshttps://www.pharmaradar360.com/article/b6af31bf580309e3PharmaRadar360en2026-04-06T10:00:00.000ZBP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertensionhttps://www.pharmaradar360.com/article/36235c9308a67a96PharmaRadar360en2026-04-06T10:00:00.000ZMultisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Riskhttps://www.pharmaradar360.com/article/cb2802a2408e6069PharmaRadar360en2026-04-06T10:00:00.000ZIn MINOCA, stratified treatment guided by MINOCA cause vs. standard care improved angina status at 1 yhttps://www.pharmaradar360.com/article/129d1e58a0c55effPharmaRadar360en2026-04-06T10:00:00.000ZIn sepsis, a tailored precision immunotherapy strategy improved organ function at 9 dhttps://www.pharmaradar360.com/article/cd65fd13e0227f4cPharmaRadar360en2026-04-06T10:00:00.000ZIn patients with painful diabetic neuropathy, pregabalin does not differ from duloxetine for painhttps://www.pharmaradar360.com/article/0186cf00f2a8c3d0PharmaRadar360en2026-04-06T10:00:00.000ZIn the ED, the Wells score plus age-adjusted D-dimer score ruled out DVT with a failure rate ≤0.8% at 3 mohttps://www.pharmaradar360.com/article/34e0a11861cdb56bPharmaRadar360en2026-04-06T10:00:00.000ZIn patients with chronic lung disease, 4 existing PE diagnostic strategies were assessedhttps://www.pharmaradar360.com/article/fa7c3ced5448eb6bPharmaRadar360en2026-04-06T10:00:00.000ZIn adults with ADHD, atomoxetine, methylphenidate, and CBT reduce symptom severity and the drugs are less tolerable vs. control at 12 wkhttps://www.pharmaradar360.com/article/24c02d3c883d7105PharmaRadar360en2026-04-06T10:00:00.000ZSummary for Patients: Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Riskhttps://www.pharmaradar360.com/article/3f84aa88f2c29ae9PharmaRadar360en2026-04-06T10:00:00.000ZAfter ischemic stroke in patients receiving aspirin, switching to another antithrombotic regimen does not reduce recurrencehttps://www.pharmaradar360.com/article/61b3a76cb326798dPharmaRadar360en2026-04-06T10:00:00.000ZFirst-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemiahttps://www.pharmaradar360.com/article/0efe197aa1861eb6PharmaRadar360en2026-04-06T10:00:00.000ZThe ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseaseshttps://www.pharmaradar360.com/article/8cad3d98cc25dfeePharmaRadar360en2026-04-06T10:00:00.000ZPlatelet Drp1 phosphorylation provides a platform for immune-based platelet function testinghttps://www.pharmaradar360.com/article/30fed1b03cacf439PharmaRadar360en2026-04-06T06:30:00.000Z大阪大学免疫学フロンティア研究センターとの共同研究による免疫性血小板減少症に関する研究成果がBlood誌に掲載https://www.pharmaradar360.com/article/30de1058add9bb79PharmaRadar360en2026-04-06T06:30:00.000ZResearch Results on Immune Thrombocytopenia from a Joint Study with Osaka University’s IFReC Published in Blood